Drug Profile
AVA 6000
Alternative Names: AVA-6000; AVA6000 pro-Doxorubicin; FAP Pro-doxorubicinLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Tufts University School of Medicine
- Developer Avacta
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Peptide drug conjugates; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours